Search for: "Pharmacia " Results 101 - 120 of 179
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
21 Feb 2016, 1:44 am
These factors were then applied for the first time in Actavis v Pharmacia [2014] EWHC 2265 (the history of which is recorded in Rose J's judgment). [read post]
2 Oct 2008, 6:00 am
I'm sure you are familiar with the old joke about how many lawyers it takes to change a light bulb.So, who were the Pfizer lawyers that were involved in the internal decisions that led to Dr. [read post]
15 Oct 2012, 1:24 am by Kevin LaCroix
    As discussed here, shareholders first sued Pharmacia and certain of its directors and officers in 2003, alleging that the company had released only part of a long-term clinical study the company had commissioned on the side effects of the drug. [read post]
15 Jul 2014, 11:44 pm by Nietzer
Today I conclude my three-part series on mergers and acquisitions under the Foreign Corrupt Practices Act (FCPA) with a review of the post-acquisition phase. [read post]
18 Feb 2014, 3:18 pm by Ronald V. Miller, Jr.
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Testosterone is a 19-carbon steroid hormone. [read post]
18 Feb 2014, 3:18 pm by Ronald V. Miller, Jr.
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Testosterone is a 19-carbon steroid hormone. [read post]
1 Mar 2010, 12:22 am by Dr. Shezad Malik
Until 1995, many patients combined Premarin, Wyeth's estrogen-based drug, with progestin-laden Provera, made by Pfizer's Pharmacia & Upjohn unit. [read post]
16 Apr 2014, 5:35 am by Ronald V. Miller, Jr.
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Researchers have long suspected a link between testosterone treatment and the risk of heart attack, though millions of men who have been taking the hormonal treatments are just now learning of the… [read post]
18 Feb 2014, 3:18 pm by Ronald V. Miller, Jr.
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Testosterone is a 19-carbon steroid hormone. [read post]
18 Feb 2014, 3:18 pm by Ronald V. Miller, Jr.
Products in this category are: Androgel (Abbvie/Abbott) Androderm (Actavis) Axirom (Eli Lilly) Bio-T-Gel (BioSante and Teva) Delatestryl (Indevus) Depo-Testosterone (Pharmacia & Upjohn Company) Fortesta (Endo) Striant (Columbia Laboratories) Testim (Auxilum/GlaxoSmithKline) Testopel (Auxilium) Testosterone is a 19-carbon steroid hormone. [read post]
20 May 2010, 7:30 am by Stephen Albainy-Jenei
The judge followed the Court of Justice’s interpretation of Article 3(d) in Pharmacia, MIT and Yissum, holding that the authorization required under 3(b) is the first authorisation to place the product on the market as “any” medicinal product. [read post]
17 Apr 2012, 4:30 am
., Pharmacia Corp., and Pfizer, Inc., in the Circuit Court of St. [read post]
25 Jan 2017, 11:25 pm
He notes that the Neurim decision seems to be inconsistent with the CJEU’s decisions in MIT, GSK, Pharmacia and Yissum. [read post]
23 Jan 2020, 12:55 pm by Alexa von Uexküll
The Neurim decision is highly controversial, as it is in conflict with the literal wording of the provisions of the SPC Regulation, as well as the previous standing case law, as evidenced by Pharmacia (C-31/03), Yissum (C-202/05) and MIT (C-431/04). [read post]
8 Jun 2013, 10:35 am by Madhulika Vishwanathan
Sugen’s appeal against the revocation was fixed for hearing on May 14th 2013 subject to the undertaking given by the appellant (Sugen) that they will not use the revoked patent against the second respondent (Cipla) in other proceedings.According to the appellant (Sugen/Pharmacia) the opposition was not sustainable (second revocation decision) due to the following grounds, which are detailed below:Consideration of Section 25(2) (b):Sugen argued that Section 25(2) (b) should have not… [read post]